Loading stock data…
$0.41-0.01 (-2.42%)
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
Dyadic International, Inc. in the Healthcare sector is trading at $0.41 with a market capitalization of $21M. Wall Street consensus targets $5.50 (2 analysts), implying a +1225.3% move over the next 12 months. The stock is currently near its 52-week low of $0.34, remaining 47.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $123,886↓ | $623,590↑ | $235,716↓ | $350,046↓ | $463,449 |
| Gross Profit | -$860,279↓ | -$168,250↓ | -$148,892↑ | -$673,957↓ | -$150,142 |
| Operating Income | -$2.05M↓ | -$1.91M↓ | -$1.52M↑ | -$1.91M↓ | -$1.71M |
| Net Income | -$2.12M↓ | -$1.95M↓ | -$1.57M↑ | -$1.98M↓ | -$1.79M |
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary ...